SCHEMBL24958731

SCHEMBL24958731

COC(=O)c1ncc(O)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HCAR2 Q8TDS4 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
CA12 O43570 3/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA7 P43166 3/20 0.38
CA9 Q16790 3/20 0.38
CA14 Q9ULX7 3/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.37
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130301 0.79 MAPK1 (0.44) MAPK1ALDH1A1KDM4EL3MBTL1HCAR2
SCHEMBL24369745 0.78 ALDH1A1 (0.46) MAPK1ALDH1A1KDM4EL3MBTL1HCAR2
SCHEMBL13260686 0.78 MAPK1 (0.43) MAPK1ALDH1A1KDM4EL3MBTL1NPSR1
SCHEMBL130300 0.78 MAPK1 (0.43) MAPK1ALDH1A1KDM4EL3MBTL1HCAR2
SCHEMBL25223823 0.78 MAPK1 (0.43) MAPK1ALDH1A1KDM4EL3MBTL1NPSR1
SCHEMBL12766570 0.78 MAPK1 (0.43) MAPK1ALDH1A1KDM4EL3MBTL1NPSR1
SCHEMBL25267530 0.75 ALDH1A1 (0.44) MAPK1ALDH1A1KDM4EL3MBTL1NPSR1
SCHEMBL21366412 0.75 MAPK1 (0.41) MAPK1ALDH1A1KDM4EL3MBTL1NPSR1
SCHEMBL13130412 0.75 CDK2 (0.51) MAPK1ALDH1A1KDM4EL3MBTL1NPSR1
SCHEMBL22890041 0.73 KDR (0.40) MAPK1ALDH1A1KDM4EL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 US disclosed
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 US disclosed
EP-4271672-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-08 EP disclosed
US-20230021705-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2023-01-26 US disclosed
WO-2022225941-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230021705-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 MAPK1 1118/4885ALDH1A1 3556/4885KDM4E 2322/4885
US-11858918-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 MAPK1 1118/4885ALDH1A1 3556/4885KDM4E 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.